Limbix’ digital therapeutic cuts depression symptoms in young people

Limbix is moving ahead with plans to file for FDA approval of its SparkRx digital therapeutic (DTx) for adolescents with symptoms of depression after reporting positive results in a clinical trial.

SparkRx uses a programme of cognitive behavioural therapy (CBT) that is designed to be used alongside treatment by a clinician, and to provide a readily-available intervention for young people when access to interpersonal psychotherapy may be limited.